Novel CAR-T cells targeting TRKB for the treatment of solid cancer
Apoptosis · 2024
DOI: 10.1007/s10495-024-01936-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, 2024. Verfasst von Dandan Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Targeting Therapy & Immunology and Laboratory of Animal Tumor Models, Cancer Center and State Key Laboratory of Respiratory Health and …. Hauptthemen laut MEDLINE: Receptor, trkB, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Brain-Derived Neurotrophic Factor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T-cell therapy is highly effective for treating blood cancers such as B-cell malignancies, however, its effectiveness as an approach to treat solid tumors remains to be further explored. Here, we focused on the development of CAR-T cell therapies targeting tropomyosin-related kinase receptor B (TRKB), a highly expressed protein that is significantly associated with tumor progression, malignancy, and drug resistance in multiple forms of aggressive solid tumors. To achieve this, we screened brain-derived neurotrophic factor (BDNF) and neurotrophin 4 (NTF4) ligand-based CAR-T cells for their efficiency in targeting the TRKB receptor in the context of solid tumors, particularly hepatocellular carcinoma and pancreatic cancer. We demonstrated that TRKB is overexpressed not only in hepatocellular carcinoma and pancreatic carcinoma cell lines but also in cancer stem-like cells (CSCs). Notably, BDNF-CAR T and NTF4-CAR T cells could not only effectively target and kill TRKB-expressing pan-cancer cell lines in a dose-dependent manner but also effectively kill CSCs. We also performed in vivo studies to show that NTF4-CAR T cells have a better potential to inhibit the tumor growth of hepatocellular carcinoma xenografts in mice, compared with BDNF-CAR T cells. Taken together, our findings suggest that CAR-T targeting TRKB may be a promising approach for developing novel therapies to treat solid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Targeting Therapy & Immunology and Laboratory of Animal Tumor Models, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecu…
- Laboratory of Metabolism and Aging Research, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. chenhy82@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
Zitieren
APA
Liang, D., Tang, J., Sun, B., He, S., Yang, D., Ma, H., Yun, Y., Zhu, Y., Wei, W., Chen, H., & Zhao, X. (2024). Novel CAR-T cells targeting TRKB for the treatment of solid cancer. Apoptosis. https://doi.org/10.1007/s10495-024-01936-7
Vancouver
Liang D, Tang J, Sun B, He S, Yang D, Ma H, et al. Novel CAR-T cells targeting TRKB for the treatment of solid cancer. Apoptosis. 2024. doi:10.1007/s10495-024-01936-7
BibTeX
@article{Liang2024,
author = {Liang, Dandan and Tang, Jie and Sun, Bin and He, Shuai and Yang, Dong and Ma, Haiyan and Yun, Yuncang and Zhu, Yongjie and Wei, Wenwen and Chen, Haiyang and Zhao, Xudong},
title = {Novel CAR-T cells targeting TRKB for the treatment of solid cancer},
journal = {Apoptosis},
year = {2024},
doi = {10.1007/s10495-024-01936-7}
}
EUVIMED